---
schema_version: "secwatch.filing_event.v1"
accession: "0001178913-26-004720"
form_type: "8-K"
ticker: "ENTXW"
cik: "0001638097"
company_name: "Entera Bio Ltd."
filed_at: "2026-10-06T12:00:20+00:00"
generated_at: "2026-10-12T16:34:57.787304+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# Entera Bio adds ex-Gilead EVP Laura Hamill to board; Yonatan Malca exits after 16 years

## Summary
- Laura Hamill, 62, appointed Class I director effective December 1, 2026; also joins the audit and corporate governance/nomination committees.
- Hamill was EVP Worldwide Commercial Operations at Gilead Sciences, leading ~2,500 employees and $22B in annual revenue; spent nearly two decades at Amgen.
- She succeeds Yonatan Malca, who steps down December 1, 2026 after 16 years of service; company says departure is not due to any disagreement.
- CEO Miranda Toledano cites Hamill's experience for late-stage execution and commercial preparedness for EB613 in osteoporosis and the oral peptide pipeline.
- Hamill currently sits on boards of Jazz Pharmaceuticals (JAZZ), BB Biotech AG and Fate Therapeutics (FATE); compensation is standard non-employee director terms under the 2018 Equity Incentive Plan.

## SEC filing metadata
- accession: 0001178913-26-004720
- form_type: 8-K
- ticker: ENTXW
- cik: 0001638097
- company_name: Entera Bio Ltd.
- filed_at: 2026-10-06T12:00:20+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1638097/000117891326004720/0001178913-26-004720-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1638097/000117891326004720/zk2636199.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001178913-26-004720
- JSON: https://secwatch.observer/filing/0001178913-26-004720.json
- Plain text: https://secwatch.observer/filing/0001178913-26-004720.txt

## Key facts
- Executive change
  Yonatan Malca departed as director at Entera Bio Ltd..
  - Action: step down
  - Role: director
  source text: On October 6, 2026, Yonatan Malca notified the Board that he would step down as a director, effective December 1, 2026.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1638097/000117891326004720/0001178913-26-004720-index.htm
- Executive change
  Laura Hamill was appointed as Class I director at Entera Bio Ltd..
  - Action: appointed
  - Role: Class I director
  source text: On October 6, 2026, the Board of Directors (the “ Board ”) of Entera Bio Ltd., a company organized under the laws of the State of Israel (the “ Company ”), appointed Laura Hamill as a Class I director of the Company, effective December 1, 2026.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1638097/000117891326004720/0001178913-26-004720-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.